Pure Global
NCT06317558

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Real-world Clinical Outcomes of Neoadjuvant Immunotherapy in NSCLC Patients: A Retrospective, Multi-center, Cohort Study (NeoIM-Lung)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Neoadjuvant immunotherapy
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Dec 31, 2027
Enrollment
4000 participants
Primary outcome

Pathological Complete Response (pCR),Disease-free survival(DFS)

Summary

The goal of this observational study is to evaluate the efficacy and long-term clinical
 outcomes of different neoadjuvant immunotherapies in NSCLC patients using the real-world
 data. The main questions it aims to answer are:
 
 - What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment?
 
 - How to determine the subgroups of patients benefit from neoadjuvant immunotherapy?
 Participants will receive neoadjuvant immunotherapy the study will analyze the
 real-world data.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06317558
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06317558 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 4000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.